JP2017524715A5 - - Google Patents

Download PDF

Info

Publication number
JP2017524715A5
JP2017524715A5 JP2017507739A JP2017507739A JP2017524715A5 JP 2017524715 A5 JP2017524715 A5 JP 2017524715A5 JP 2017507739 A JP2017507739 A JP 2017507739A JP 2017507739 A JP2017507739 A JP 2017507739A JP 2017524715 A5 JP2017524715 A5 JP 2017524715A5
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
binding portion
specifically binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017507739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524715A (ja
JP6654187B2 (ja
Filing date
Publication date
Priority claimed from GBGB1414270.7A external-priority patent/GB201414270D0/en
Priority claimed from GBGB1507541.9A external-priority patent/GB201507541D0/en
Application filed filed Critical
Priority claimed from PCT/EP2015/068598 external-priority patent/WO2016023960A1/en
Publication of JP2017524715A publication Critical patent/JP2017524715A/ja
Publication of JP2017524715A5 publication Critical patent/JP2017524715A5/ja
Application granted granted Critical
Publication of JP6654187B2 publication Critical patent/JP6654187B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017507739A 2014-08-12 2015-08-12 抗ｃｄ４０抗体を用いた併用療法 Active JP6654187B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1414270.7 2014-08-12
GBGB1414270.7A GB201414270D0 (en) 2014-08-12 2014-08-12 Antibodies
GB1422614.6 2014-12-18
GB201422614 2014-12-18
GBGB1507541.9A GB201507541D0 (en) 2015-05-01 2015-05-01 Antibodies
GB1507541.9 2015-05-01
PCT/EP2015/068598 WO2016023960A1 (en) 2014-08-12 2015-08-12 Combination therapies with anti cd40 antibodies

Publications (3)

Publication Number Publication Date
JP2017524715A JP2017524715A (ja) 2017-08-31
JP2017524715A5 true JP2017524715A5 (https=) 2018-09-27
JP6654187B2 JP6654187B2 (ja) 2020-02-26

Family

ID=53836090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017507739A Active JP6654187B2 (ja) 2014-08-12 2015-08-12 抗ｃｄ４０抗体を用いた併用療法

Country Status (25)

Country Link
US (3) US11149090B2 (https=)
EP (3) EP3180087B1 (https=)
JP (1) JP6654187B2 (https=)
KR (1) KR102443258B1 (https=)
CN (3) CN119280407A (https=)
AU (1) AU2015303164B2 (https=)
CA (1) CA2957146A1 (https=)
CL (1) CL2017000335A1 (https=)
CO (1) CO2017001317A2 (https=)
CR (1) CR20170096A (https=)
DK (1) DK3180087T3 (https=)
EA (1) EA201790339A1 (https=)
EC (1) ECSP17008984A (https=)
ES (1) ES2725463T3 (https=)
IL (1) IL250512B (https=)
MA (1) MA47472A (https=)
MX (1) MX382549B (https=)
NI (1) NI201700015A (https=)
PE (1) PE20170680A1 (https=)
PH (1) PH12017500229A1 (https=)
SG (1) SG11201701070WA (https=)
SV (1) SV2017005380A (https=)
UA (1) UA119783C2 (https=)
WO (1) WO2016023960A1 (https=)
ZA (1) ZA201701126B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
EP3936137A1 (en) 2013-02-07 2022-01-12 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
CN115043943A (zh) 2015-05-15 2022-09-13 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
IL300122A (en) 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
IL260021B (en) 2015-12-14 2022-09-01 Macrogenics Inc Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
US11859002B2 (en) * 2016-05-13 2024-01-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2018011421A1 (en) * 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
EP3532505A4 (en) 2016-10-25 2019-12-25 Urogen Pharma Ltd. BODY CAVES IMMUNODULATING TREATMENTS
CN110114089A (zh) * 2016-11-02 2019-08-09 埃派斯进有限公司 组合中的抗cd40抗体及其使用方法
CN110072553B (zh) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
EP3569616B1 (en) * 2017-01-13 2021-09-29 Taizhou Hanzhong Biopharmaceutics, Inc. Monoclonal antibody against pd-1 and applications thereof
WO2018160917A1 (en) * 2017-03-03 2018-09-07 Janssen Biotech, Inc. Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer
SG11202000198QA (en) 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
US12053505B2 (en) 2017-08-31 2024-08-06 Multimmune Gmbh Hsp70 based combination therapy
MX2020009510A (es) * 2018-03-13 2021-08-05 Hibercell Inc Inmunoterapia combinada de beta glucano y agonista cd40.
EP3807320A4 (en) * 2018-06-12 2022-03-23 BioNTech US Inc. POLYTHERAPY INCLUDING A VACCINE BASED ON NEO ANTIGENS
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
CN112912395B (zh) * 2018-08-20 2024-08-23 辉瑞公司 抗gdf15抗体、组合物和使用方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN113302205B (zh) 2018-11-15 2024-12-06 综合医院公司 激动性肿瘤坏死因子受体超家族多肽
ES3016535T3 (en) 2018-11-23 2025-05-09 Strike Pharma Ab Bi-specific conjugates
BR112021009835A2 (pt) * 2018-11-30 2021-08-17 Jiangsu Hengrui Medicine Co., Ltd. anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
AU2020284706A1 (en) * 2019-05-28 2021-12-16 Alligator Bioscience Ab Method of providing safe administration of an anti-CD40 antibody
EP4027998A1 (en) 2019-09-09 2022-07-20 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
US20230055235A1 (en) * 2019-12-27 2023-02-23 Interoligo Corporation. Anti-cancer immunotherapeutic composition for treating cancer
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
CN113861292A (zh) * 2020-06-30 2021-12-31 百奥泰生物制药股份有限公司 抗cd40抗体或抗原结合片段及其应用
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
EP4415757A4 (en) * 2021-10-15 2025-10-08 Univ Rockefeller COMBINATION OF ANTI-CD40 ANTIBODIES AND IL-15 FOR THE TREATMENT OF CANCER
WO2023076768A1 (en) * 2021-10-26 2023-05-04 Navicure Biopharmaceuticals Limited Combination therapies against cancer and infectious diseases
WO2023247050A1 (en) 2022-06-23 2023-12-28 Alligator Bioscience Ab Combination therapies
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU3374795A (en) 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
EP1341909B2 (en) 2000-12-12 2012-04-11 Alligator Bioscience AB A method for in vitro molecular evolution of protein function
CA2658221C (en) 2001-04-27 2012-11-27 Kyowa Kirin Co., Ltd. Anti-cd40 monoclonal antibody
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
DK1504098T4 (da) 2002-05-17 2011-05-23 Alligator Bioscience Ab Fremgangsmåde til molekyulær udvikling in vitro af proteinfunktion
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
WO2006073443A2 (en) 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
US8303955B2 (en) 2005-05-26 2012-11-06 Seattle Genetics, Inc. Humanized anti-CD40 antibodies and their methods of use
GB0620894D0 (en) * 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
CA2712989C (en) 2008-01-23 2015-10-27 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
CA2735421A1 (en) * 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
CN102695772B (zh) * 2009-09-16 2015-09-16 纳幕尔杜邦公司 装有反式-1,1,1,4,4,4-六氟-2-丁烯的冷却器设备以及在其中制冷的方法
GB201006096D0 (en) 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
MX368257B (es) 2011-08-01 2019-09-26 Genentech Inc Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2014121099A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
CN105611944A (zh) 2013-12-20 2016-05-25 豪夫迈·罗氏有限公司 抗ang2抗体和cd40激动剂的组合疗法
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
KR20250004095A (ko) 2015-04-17 2025-01-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
CN107810198B (zh) 2015-05-29 2021-09-03 艾伯维公司 抗cd40抗体及其用途
BR112017027549A2 (pt) 2015-06-29 2018-09-11 Bristol-Myers Squibb Company anticorpo para cd40
CN107922500A (zh) 2015-06-29 2018-04-17 洛克菲勒大学 具有增强的激动剂活性的抗cd40抗体

Similar Documents

Publication Publication Date Title
JP2017524715A5 (https=)
JP2016537383A5 (https=)
PH12019502785A1 (en) Anti trbc1 antigen binding domains
FI3799885T3 (fi) Lymfosyyttien estoreittien neutralointi
JP2017500057A5 (https=)
WO2019086497A3 (en) Combination therapy with targeted ox40 agonists
JP2015532292A5 (https=)
JP2017048240A5 (https=)
JP2018516911A5 (https=)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JP2022500410A5 (https=)
JP2014205674A5 (https=)
RU2014138039A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
JP2020502271A5 (https=)
WO2015200806A3 (en) Humanized anti-tau antibodies
EP4653463A3 (en) Antibodies
WO2016055432A3 (en) Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents
IL253462B (en) Cancer treatment with monoclonal antibodies against latency-associated peptide
HRP20201022T1 (hr) Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba
NZ608206A (en) Antibodies that bind myostatin, compositions and methods
JP2022512750A5 (https=)
WO2016090024A4 (en) Combination therapy for treatment of cancer
JP2022512851A5 (https=)
JP2022516351A5 (https=)
JP2022513350A5 (https=)